Q2 Holdings, Inc. QTWO

Bloom Energy (BE) earned nearly 90% of its latest quarterly revenue from selling its power equipment. In fiscal Q2 2026, a record quarter for the company, those equipment sales reached $935 million. Over the past year, the stock returned 314%, against 16.8% for the S&P 500. A stock that has run this far would be exposed if those sales slowed. Should investors in Bloom Energy worry that its record quarter came mostly from one kind of sale.

Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.

Coherent (COHR) and Amphenol (APH) both sell connections inside AI data centers, but Coherent relies on that business more. Data center and communications made 79% of Coherent's latest quarterly revenue. At Amphenol, sales from IT datacom made up 43% of Q2 2026 sales, and communications networks another 11%. At 68.6 times the past twelve months of profit, Coherent's price makes sense only if its orders become sales and cash. So what does Amphenol offer you that Coherent does not.

Caterpillar's shifting revenue mix reveals a company changing its core narrative. Management sounds notably different on its earnings calls today compared to a year ago. Through 2025, leadership kept pointing to one specific sales tool for its construction machines. However, in the fiscal Q2 2026 call, management pivoted to lead with data centers instead. Construction is still about a third of Caterpillar's revenue, so you should care when management changes how it talks about a business that si

Look at the breakdown of Intuitive Surgical's revenue streams—Instruments and Accessories alone generate roughly 60% of the top line on a per-procedure basis. That tight link between surgery volume and cash flow explains why investors reacted so sharply when Intuitive noted in its fiscal Q2 2026 call that U.S. procedure growth had slowed. With recurring earnings visibility clouded, how much downside risk is the market actually pricing in.

Q2 Holdings (QTWO) has been moving without a clear headline catalyst, which often pushes investors to focus squarely on fundamentals such as recent returns, revenue trends and profitability when reassessing the stock. Recent trading tells a mixed story for Q2 Holdings. The share price has slipped over the past month, with a 1-day move down 1.84%, a 7-day share price return down 4.89% and a 30-day share price return down 15.40%, even though the 90-day share price return is up 14.55%. Over a...

If you own CrowdStrike (CRWD), one worry stands out: did its best quarter come from a burst of AI urgency that will fade? Management called fiscal Q2 2027 the company's very best quarter. Over the last year, CrowdStrike stock returned 112%, against 18.0% for the S&P 500. A $10,000 holding a year ago is now worth about $21,200. Which threat could take that gain back.

Alkami Technology, Inc. (NASDAQ:ALKT) just lost the strategic optionality that had surrounded its stock. After a review of potential alternatives, the digital banking software provider decided to remain independent, sending shares nearly 20% lower on September 23. JPMorgan subsequently downgraded the stock to Underweight. But the bigger question is whether the selloff reflects weaker fundamentals […]

Everpure (P) grew revenue 38% from a year earlier in fiscal Q2 2027, and management expects that pace to last for some time. The stock costs 144.1 times its past year of earnings, against 22.4 for the S&P 500. Two things must hold. Customers must keep paying far higher prices, and Everpure must keep getting parts at costs it can absorb. Is the cost of Everpure's parts already climbing.

Arista Networks (ANET) ended fiscal Q2 2026 with about $9.7 billion of multi-year purchase commitments. These are promises to buy from its suppliers over several years. If demand for its switches slows, those promises remain. Will the company's sales keep pace with what it has promised its suppliers.

Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%. Much of the market has focused on moderating U.S. procedure growth. The more telling number is 144 trade-ins in fiscal Q2 2026, up from 83 a year earlier. Most came from customers moving to the new da Vinci 5 robot. Those trade-ins matter most if upgrades continue and each surgery also earns more. Is that number a blip, or are customers still trading up.

If you own CVS Health (CVS), the primary focus shifts from 2026 execution toward potential headwind variables heading into 2027. Management raised its 2026 earnings outlook on its fiscal Q2 2026 call in August. It also gave an early read on 2027, a quarter sooner than usual. One warning in that read came with no number. Over the past three months, the shares lost 15.2%, while the S&P 500 gained 5.0%. What is the 2027 problem CVS would not put a number on.

Advanced Micro Devices (AMD) has stopped leading with the problem that opened its call a year ago. That problem was keeping one of its accelerators out of China. The latest call was fiscal Q2 2026. This time, management did not lead with the subject at all. So what was AMD leading with back then.

If you hold NVIDIA (NVDA) stock, one number deserves your attention: roughly a quarter. That is the share of fiscal 2028 business management expects from AI labs it will back with its own balance sheet. NVIDIA's revenue more than doubled year over year in fiscal Q2 2027, so this number is easy to miss. An important thing to watch is how much future demand depends on NVIDIA backing its own customers.

Once every planned deal is signed, Micron Technology (MU) expects about 40% of its revenue to sit under fixed prices or price ceilings near calendar Q2 2026 market levels. That matters because higher pricing drove most of the jump to a record gross margin in fiscal Q3 2026. The contracts typically run five years, and the largest also lock in a floor. But the ceiling is the number a holder should worry about most.

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

AI is moving from shiny demo to real-world risk story, as regulators, security experts, and Big Tech leaders argue over how far powerful models should go. That debate creates a window for investors. Some companies exposed to this news may need to spend more to keep up. Others might gain trust and a larger share of enterprise AI budgets. This article examines three stocks from the screener that may be positioned for this turning point. The three stocks covered below are just a sample from this...

Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.

Snap (SNAP) generates free cash worth 7.4% of its market value a year, against 4.5% for the median S&P 500 company. A yield that high usually points one of two ways: a bargain, or a business the market expects to shrink. Snap is not shrinking: revenue grew 19% year over year in Q2 2026. So the market is pricing something else, the profit that sits underneath the cash.

Lululemon Athletica (LULU) has fallen about 22% since late August and now trades at its lowest price in the past year. Is that a chance to buy? Its own record says dips here have paid off more often than not. The catch is that the recent ones have not. And Lululemon's own women's leggings sales, in a category it leads, fell about 20% in fiscal Q2 2026.